Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.

Leu K, Boxerman JL, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB, Ellingson BM.

AJNR Am J Neuroradiol. 2016 Apr 14. [Epub ahead of print]

PMID:
27079371
2.

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.

Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.

J Magn Reson Imaging. 2016 Mar 12. doi: 10.1002/jmri.25227. [Epub ahead of print]

PMID:
26971534
3.

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.

Am J Clin Oncol. 2015 Dec 9. [Epub ahead of print]

PMID:
26658237
4.

Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Shiroishi MS, Boxerman JL, Pope WB.

Neuro Oncol. 2016 Apr;18(4):467-78. doi: 10.1093/neuonc/nov179. Epub 2015 Sep 12. Review.

PMID:
26364321
5.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP.

Neuro Oncol. 2015 Nov;17(11):1538-9. doi: 10.1093/neuonc/nov163. Epub 2015 Sep 11. No abstract available.

PMID:
26361983
6.

Standardized Brain Tumor Imaging Protocol for Clinical Trials.

Goldmacher GV, Ellingson BM, Boxerman J, Barboriak D, Pope WB, Gilbert M.

AJNR Am J Neuroradiol. 2015 Oct;36(10):E65-6. doi: 10.3174/ajnr.A4544. Epub 2015 Sep 10. No abstract available.

PMID:
26359146
7.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

PMID:
26250565
8.

Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas.

Boxerman JL, Ellingson BM.

Top Magn Reson Imaging. 2015 Jun;24(3):127-36. doi: 10.1097/RMR.0000000000000054. Review.

PMID:
26049816
9.

ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Welker K, Boxerman J, Kalnin A, Kaufmann T, Shiroishi M, Wintermark M; American Society of Functional Neuroradiology MR Perfusion Standards and Practice Subcommittee of the ASFNR Clinical Practice Committee.

AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51. doi: 10.3174/ajnr.A4341. Epub 2015 Apr 23.

PMID:
25907520
10.

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Int J Oncol. 2015 May;46(5):1883-92. doi: 10.3892/ijo.2015.2891. Epub 2015 Feb 11.

11.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

PMID:
25646027
12.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2014 Nov 26. [Epub ahead of print]

PMID:
25436828
13.

Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.

Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM.

Clin Neurol Neurosurg. 2014 Oct;125:125-30. doi: 10.1016/j.clineuro.2014.06.011. Epub 2014 Jul 29. Review.

PMID:
25127260
14.

Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.

Shiroishi MS, Castellazzi G, Boxerman JL, D'Amore F, Essig M, Nguyen TB, Provenzale JM, Enterline DS, Anzalone N, Dörfler A, Rovira À, Wintermark M, Law M.

J Magn Reson Imaging. 2015 Feb;41(2):296-313. doi: 10.1002/jmri.24648. Epub 2014 May 12. Review.

PMID:
24817252
15.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

16.

An efficient computational approach to characterize DSC-MRI signals arising from three-dimensional heterogeneous tissue structures.

Semmineh NB, Xu J, Boxerman JL, Delaney GW, Cleary PW, Gore JC, Quarles CC.

PLoS One. 2014 Jan 8;9(1):e84764. doi: 10.1371/journal.pone.0084764. eCollection 2014.

17.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

18.

Prenatal MRI characterization of brainstem glioma.

Swenson DW, Nickel BJ, Boxerman JL, Klinge PM, Rogg JM.

Pediatr Radiol. 2013 Oct;43(10):1404-7. doi: 10.1007/s00247-013-2706-1. Epub 2013 May 16.

PMID:
23677423
19.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

20.

Advances in myelin imaging with potential clinical application to pediatric imaging.

Spader HS, Ellermeier A, O'Muircheartaigh J, Dean DC 3rd, Dirks H, Boxerman JL, Cosgrove GR, Deoni SC.

Neurosurg Focus. 2013 Apr;34(4):E9. doi: 10.3171/2013.1.FOCUS12426. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk